- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study2011 | 3. lékařská fakulta
- Volba mezi inhibitory DPP4 a SGLT2 u diabetiků 2. typu nekompenzovaných na metforminu2018 | 2. lékařská fakulta
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment2011 | 3. lékařská fakulta
- Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial2015 | Lékařská fakulta v Hradci Králové
- Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY (R) study2022 | 1. lékařská fakulta
- Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects2014 | 1. lékařská fakulta
- DPP-4 inhibitory a autoimunita2014 | 1. lékařská fakulta, 3. lékařská fakulta
- Sitagliptin2008 | 2. lékařská fakulta
- Saxagliptin2013 | 1. lékařská fakulta
- Kardiovaskulární systém a gliptiny2014 | 2. lékařská fakulta
- Linagliptin v léčbě diabetes mellitus 2. typu: současný stav a perspektivy2013 | 1. lékařská fakulta
- Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections2022 | 1. lékařská fakulta
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes2020 | 1. lékařská fakulta
- The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia2021 | 2. lékařská fakulta
- Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia2022 | 2. lékařská fakulta